Catalog3 refs
Retatrutide
Metabolicglp1Weight LossResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
CirculationSkin
Overview
Retatrutide is a once-weekly injectable peptide that acts as a triple agonist targeting GIP, GLP-1, and glucagon receptors. It combines three hormone signals into one molecule to curb appetite, support insulin response, and increase energy expenditure and fat burning. In phase 2 and phase 3 trials, it has produced some of the largest weight loss ever recorded for a drug, up to 28.3% mean weight loss at 80 weeks. It is investigational, made by Eli Lilly, and not yet FDA approved.
Primary Uses
Weight loss
Appetite suppression
Improved glycemic control
Improved HbA1c
Reduced liver fat
Improved blood pressure
Improved lipid profiles
obesity
type 2 diabetes
nonalcoholic fatty liver disease (NAFLD/NASH)
liver fat reduction
Obesity and diabetes trials
Triple incretin pharmacology
Weight-loss studies
Cardiometabolic disease research
Glycemic control
Cardiovascular/metabolic improvement
Hepatic fat reduction
Lipid improvement
Blood pressure optimization
blood glucose reduction
increased energy expenditure
Obesity treatment
Improving blood sugar in prediabetes
Protocol Reference
Dose
0.5–2.0 mg weekly
Frequency
Once Or Twice Weekly, Same Day Each Week
Half-life
~6 Days
Route
Subcutaneous
Evidence
Human Clinical Data Available / Phase 3 / Phase 3 clinical trials / Extensively Studied / Clinical trials ongoing / Phase 3 Clinical Trials (disputed)
Research References· 22
Research Models
HumanMouseRatrodents
Also in Metabolic